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Abstract
Studies suggest that infection with highly prevalent Pseudomonas
aeruginosa clones in cystic ﬁbrosis (CF) is associated with an
unfavourable clinical outcome. We studied the clinical character-
istics of patients infected with a recently described, highly preva-
lent P. aeruginosa clone (ST406) in two CF centres in The
Netherlands. Multilocus sequence typing data were available for
219 patients, of whom 40 (18.3%) were infected with ST406 and
179 with other sequence types. ST406 infection was indepen-
dently associated with age, having a sibling with ST406 infection
and use of inhaled antibiotics, but not with unfavourable clinical
outcome, suggesting that high transmissibility is not necessarily
associated with high virulence.
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Of patients with cystic ﬁbrosis (CF), 60–80% become chroni-
cally infected with Pseudomonas aeruginosa [1], which is asso-
ciated with increased morbidity and mortality [2]. The
original perception that each patient acquires his or her own
P. aeruginosa strain from the environment and that transmis-
sion only occurs in siblings with CF [3] is disputed by later
reports of the occurrence of highly prevalent clones of
P. aeruginosa in CF centres in Australia and Europe. Many of
these clones are highly resistant to antibiotics and appear to
be associated with unfavourable clinical outcome [4–8]. To
prevent the further spread of transmissible P. aeruginosa
clones, infection control policies and measures have been
put into practice in several countries [9,10]. Recently, a
cross-sectional study using multilocus sequence typing
(MLST) revealed a highly prevalent clone in the patient popu-
lation of two large CF centres in The Netherlands (together,
382 Clinical Microbiology and Infection, Volume 17 Number 3, March 2011 CMI
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 380–385
these centres manage about 45% of the total Dutch CF pop-
ulation), designated ST406 [11]. Genetically, this clone was
not closely related to any of the earlier described ‘epidemic’
P. aeruginosa clones, and it has no speciﬁc antibiotic resis-
tance proﬁle. We aimed to study whether infection with
ST406 is associated with unfavourable clinical outcome in the
CF patient population of the CF centres of Utrecht and The
Hague, The Netherlands.
In these centres, segregation policies have been adopted
since 2005. Sputum samples and throat swabs were collected
regularly and were cultured according to the standard diag-
nostic laboratory protocols of each CF centre. Phenotypically
different isolates were collected by randomly taking one
P. aeruginosa colony of each different colony morphology
(based on rough, smooth and mucoid characteristics and col-
ony size) per sample. MLST was performed on all phenotypi-
cally different isolates of the ﬁrst P. aeruginosa-positive
culture from each patient in 2007 (Utrecht) and the ﬁrst half
of 2008 (The Hague), as described in a previous study [11].
Patients were designated as chronically infected if P. aerugin-
osa was present in more than 50% of all cultures performed
in 2006 and 2007. Patients infected with more than one
sequence type including ST406, were regarded as being
infected with ST406. Demographic data, CF genotype and
clinical parameters were collected from the centres’ data-
bases. All patients gave written informed consent for storage
and evaluation of their clinical data in the CF database for
scientiﬁc purposes. Statistical analyses were performed using
SPSS for Windows version 15.0.1 (SPSS, Chicago, IL, USA).
In total, 561 patients were under treatment at the CF
centres of Utrecht and The Hague, excluding patients with a
history of lung transplantation. Cultures were collected from
515 patients (92%), and ten patients were excluded because
of chronic Burkholderia cepacia infection. There were 265
patients (52%) chronically infected with P. aeruginosa, and
MLST data were available for 219 of these. Forty (18%)
patients were infected with ST406, and 179 patients were
infected with other sequence types (not ST406). Table 1
shows that chronic P. aeruginosa infection is associated with
increased age, increased use of inhaled antibiotics and
decreased lung function. Factors associated with infection
with the highly prevalent clone ST406 are shown in Table 2.
There was no signiﬁcant association between sequence type
and percentage of predicted forced expiratory volume in 1 s
, body mass index and the number of hospitalization days. In
the multiple logistic regression model, the presence of a sib-
ling with ST406, age and the use of inhaled antibiotics were
independently associated with ST406 infection. This strong
association with having a sibling with the same P. aeruginosa
sequence type was not a unique feature of ST406: the pro-
portion of concordant siblings was not signiﬁcantly different
between those infected with ST406 (75%) and those infected
with sporadic sequence types (58%) (p 0.67).
The observations of an association between chronic
P. aeruginosa infection and increased age, decreased lung func-
tion and increased use of inhaled antibiotics are in accordance
with the literature [12,13]. However, the ﬁndings regarding
the Dutch clone ST406 are different from those described in
other countries, as many of the published clones are associ-
ated with decreased lung function [4,6,7], decreased nutri-
tional status [6] and/or increased treatment requirements
[4,5,7,14,15]. An important difference between the clones
TABLE 1. Association between clinical and demographic variables and chronic Pseudomonas aeruginosa infection (results of
logistic regression analysis) in 505 cystic ﬁbrosis patients
Simple logistic regression Multiple logistic regression
OR (95% CI)
Pseudomonas-positive
(n = 265)
Pseudomonas-negative
(n = 240) p OR (95% CI) p
Male gender 0.85 (0.60–1.21) 133 (50.2%) 130 (54.2%) 0.37
Age (years)
1–12 (reference category) 42 (15.8%) 118 (49.2%) <0.001 <0.001
13–24 5.20 (3.21–8.44) 100 (37.7%) 54 (22.5%) <0.001 3.69 (1.98–6.88) <0.001
‡25 5.08 (3.21–8.05) 123 (46.4%) 68 (28.3%) <0.001 2.31 (1.17–4.57) 0.02
Homozygosity for dF508 1.39 (0.96–2.01) 154 (63.4%) 127 (55.5%) 0.08 1.62 (0.99–2.64) 0.05
Pancreatic insufﬁciency 1.02 (0.65–1.60) 217 (81.9%) 196 (81.7%) 0.95
ABPA 2.32 (1.30–4.16) 42 (15.8%) 18 (7.5%) <0.01 1.49 (0.74–3.00) 0.27
Diabetes 2.26 (1.38–3.70) 59 (22.3%) 27 (11.3%) <0.01 0.90 (0.47–1.70) 0.74
rhDNase 2.67 (1.84–3.88) 132 (49.8%) 65 (27.1%) <0.001 1.15 (0.69–1.91) 0.59
Inhaled antibiotics 10.66 (6.90–16.47) 173 (65.3%) 36 (15.0%) <0.001 7.38 (4.46–12.19) <0.001
Hospitalization days 1.02a (1.01–1.04) 7.59 (SD 16.7) 3.50 (SD 13.2) <0.01 1.00a (0.99–1.02) 0.82
BMI z-score 0.92a (0.78–1.09) )0.40 (SD 1.1) )0.31 (SD 1.0) 0.35
FEV1 (% of predicted value) 0.97
a (0.96–0.98) 63.78 (SD 24.0) 82.39 (SD 24.2) <0.001 0.98a (0.97–0.99) 0.003
ABPA, allergic bronchopulmonary aspergillosis; BMI, body mass index; FEV1, forced expiratory volume in 1 s; rhDNase, recombinant human DNase; SD, standard deviation.
aChange per unit of variable.
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reported in the literature and ST406 investigated in the pres-
ent study is the lack of a speciﬁc antibiotic resistance proﬁle
for ST406 [16–18]. This might partly explain the increased
morbidity and prolonged respiratory exacerbations in
patients with reported widely distributed clones. The reason
for an association between infection with ST406 and
increased use of inhaled antibiotics can only be speculated on.
Increased persistence of ST406 during treatment with inhaled
antibiotics is a possibility. The ﬁnding of a high sibling concor-
dance for sequence types illustrates the importance of house-
hold transmission in general.
As ST406 was not associated with unfavourable outcome
in the present study, it appears that ST406 is not, unlike the
other reported highly prevalent clones, characterized by
increased virulence. Analogously to decreased in vitro viru-
lence in two highly prevalent clones in Copenhagen [19], the
results presented here suggest that ST406 might be another
clone that is highly transmissible but not highly virulent. Lab-
oratory studies are needed to investigate the in vitro charac-
teristics of ST406.
A limitation to our study is the cross-sectional nature,
which raises questions about the duration of ST406 infec-
tion. It is possible that ST406 was introduced into the
studied CF population only recently, and therefore has had
only a short time to exert any possible effect on clinical
status. However, in a 2001 study on the transmission of
P. aeruginosa during summer camps for CF patients in The
Netherlands [20], the most prevalent ampliﬁed fragment
length polymorphism type was found to be ST406 upon
MLST typing [11]. This suggests that ST406 has been pres-
ent in the Dutch CF population for at least 6 years.
Furthermore, as the segregation policy was adopted in
2005, it seems most plausible that the spread of ST406
took place before 2005.
In conclusion, although chronic infection with P. aeruginosa
was associated with decreased lung function, infection with
ST406 was not associated with unfavourable clinical outcome
in this population, suggesting that ST406 is, unlike other
reported widely distributed clones, not highly virulent.
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TABLE 2. Association between clinical and demographic variables and ST406 infection (results of logistic regression analysis)
in 219 chronically infected cystic ﬁbrosis (CF) patients
Simple logistic regression Multiple logistic regression
OR (95% CI) ST406 (n = 40) Other ST (n = 179) p OR (95% CI) p
CF centre Utrecht
(vs. CF centre The Hague)
3.16 (1.38–7.24) 32 (80.0%) 100 (55.9%) <0.01 2.13 (0.70–6.41) 0.18
Male gender 0.97 (0.49–1.92) 20 (50.0%) 91 (50.8%) 0.92
Age (years)
1–12 (reference category) 1 (2.5%) 32 (17.9%) <0.001 <0.001
13–24 23.68 (3.09–181.25) 37 (92.5%) 50 (27.9%) 0.002 24.83 (2.59–237.73) 0.005
‡25 0.66 (0.06–7.52) 2 (5.0%) 97 (54.2%) 0.74 1.16 (0.08–16.61) 0.91
Homozygosity for dF508 1.93 (0.88–4.22) 30 (75.0%) 98 (60.9%) 0.10
Sibling with ST406 42.61 (9.11–199.32) 13 (32.5%) 2 (1.1%) <0.001 20.27 (3.62–113.58) 0.001
Pancreatic insufﬁciency 1.10 (0.42–2.85) 34 (85.0%) 150 (83.8%) 0.85
ABPA 0.35 (0.10–1.19) 3 (7.5%) 34 (19.0%) 0.09
Diabetes 1.01 (0.44–2.29) 9 (22.5%) 40 (22.3%) 0.98
rhDNase 0.89 (0.44–1.76) 18 (45.0%) 86 (48.0%) 0.73
Inhaled antibiotics 2.28 (0.99–5.24) 32 (80.0%) 114 (63.7%) 0.05 3.42 (1.14–10.24) 0.03
Hospitalization days 1.01a (0.99–1.03) 10.8 (SD 26.9) 7.4 (SD 14.6) 0.28
BMI z-score 0.91a (0.67–1.23) )0.5 (SD 1.2) )0.4 (SD 1.1) 0.53
FEV1 (% of predicted value) 1.01
a (1.00–1.02) 67.3 (SD 27.3) 61.9 (SD 23.5) 0.20
ABPA, allergic bronchopulmonary aspergillosis; BMI, body mass index; FEV1, forced expiratory volume in 1 s; rhDNase, recombinant human DNase; SD, standard deviation.
aChange per unit of variable.
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